<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353557</url>
  </required_header>
  <id_info>
    <org_study_id>Geneplus2020BC01</org_study_id>
    <nct_id>NCT04353557</nct_id>
  </id_info>
  <brief_title>ctDNA Monitoring in Early Breast Cancer</brief_title>
  <official_title>Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geneplus-Beijing Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Army Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Geneplus-Beijing Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in
      patients with early breast cancer and assessing the prognostic value and treatment outcome
      monitoring of ctDNA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive ctDNA detection at first post-operative timepoint</measure>
    <time_frame>1 month post-surgery</time_frame>
    <description>The proportion of patients with ctDNA positivity as assessed by the blood sample taken at first post-operative timepoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive ctDNA detection at post-operative timepoints</measure>
    <time_frame>6/12/18/24/30 months</time_frame>
    <description>The proportion of patients with ctDNA positivity as assessed by the blood sample taken at other post-operative timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between ctDNA detection and time to recurrence</measure>
    <time_frame>1 month post-surgery</time_frame>
    <description>Time to recurrence of subgroups with detectable ctDNA and undetectable ctDNA comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between ctDNA detection and time to recurrence</measure>
    <time_frame>6/12/18/24/30 months</time_frame>
    <description>Time to recurrence of subgroups with detectable ctDNA and undetectable ctDNA</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumor and plasma specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage I-III breast cancer who planed to receive curative-intent treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 to 80 years old

          2. Histologically proven primary breast cancer with clinical stageI-III

          3. Patients with neoadjuvant therapy, and/or radical surgery/breast conserving surgery,
             adjuvant chemotherapy and target therapy (Her2+), radiotherapy (if indicated).

          4. Expected to achieve R0 resection.

          5. Estimated lifetime is more than 3 months.

          6. Signed Informed Consent Form

          7. Consent to provide research blood samples.

        Exclusion Criteria:

          1. Patients intended to receive adjuvant chemotherapy with Eastern Cooperative Oncology
             Group (ECOG) performance status 3, 4 or 5.

          2. Patients intended to receive postoperative radiotherapy with Eastern Cooperative
             Oncology Group (ECOG) performance status 5.

          3. Prior diagnosis of cancer in the previous 5 years, other than for basal cell carcinoma
             of the skin or cervical carcinoma in situ.

          4. Presence of any systemic illness incompatible with participation in the clinical trial
             or inability to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yan Xu, M.D.</last_name>
    <phone>(+86)159 2310 0038</phone>
    <email>xy931@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Army Medical Center of PLA, China</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Xu, M.D.</last_name>
      <phone>(+86)159 2310 0038</phone>
      <email>xy931@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

